Victory Capital Management Inc. Sells 952 Shares of argenx SE (NASDAQ:ARGX)

Victory Capital Management Inc. lowered its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 60.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 610 shares of the company's stock after selling 952 shares during the period. Victory Capital Management Inc.'s holdings in argenx were worth $375,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Steward Partners Investment Advisory LLC increased its stake in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after purchasing an additional 20 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its stake in shares of argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock valued at $416,000 after buying an additional 22 shares during the period. Choreo LLC lifted its stake in shares of argenx by 4.4% in the 4th quarter. Choreo LLC now owns 551 shares of the company's stock valued at $342,000 after purchasing an additional 23 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of argenx by 4.2% during the fourth quarter. IFP Advisors Inc now owns 641 shares of the company's stock valued at $394,000 after acquiring an additional 26 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

ARGX has been the subject of several analyst reports. Wells Fargo & Company boosted their price target on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial reissued a "buy" rating and set a $700.00 price target (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. HC Wainwright upped their price target on shares of argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Piper Sandler raised their price target on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, argenx has a consensus rating of "Moderate Buy" and a consensus price target of $687.00.

argenx Stock Performance

Shares of NASDAQ ARGX traded down $21.86 during mid-day trading on Wednesday, reaching $583.66. 295,377 shares of the company traded hands, compared to its average volume of 282,889. The company's fifty day moving average is $632.24 and its two-hundred day moving average is $601.12. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The stock has a market cap of $35.46 billion, a PE ratio of -663.25 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.